

PPRI Advisory Board meeting

PPRI Secretariat

13 February 2024, 13 – 14 h CET



Gesundheit Österreich
GmbH ● ● ●

Agenda

- 1) Welcome and round of introduction
- 2) PPRI Conference (Vienna, 25-26 April 2024)
- 3) PPRI Network Meeting (Vienna, 24 April 2024)
- 4) Outlook on 2024 PPRI activities and PPRI@20
- 5) PPRI Advisory Board Term
- 6) AOB



Welcome Round of introduction Group picture



PPRI Conference 2024

25-26 April 2024



Gesundheit Österreich
GmbH 

PPRI Conference 2024

Ensuring access to affordable medicines through innovative policies

25-26 April 2024

Location:

Palais Niederösterreich, Herrengasse 13,
1010 Vienna (Austria)



PPRI Conference 2024

Objectives

We are committed to making our contribution to affordable, equitable and sustainable access to safe, effective and quality essential medicines worldwide, with a focus on Europe. Thus, we are pleased to provide a **platform for thought leaders, experts and researchers in the pharmaceutical field** to:

- **present research findings** and **cutting-edge academic analyses** as well as to **showcase best practice examples** of pharmaceutical pricing and reimbursement policies;
- discuss **current challenges** and **develop strategies** to tackle them;
- **support policy makers** by offering tools so that they can be well prepared and equipped to address the future challenges, and
- **allow for networking.**

PPRI Conference 2024 – Scientific Programme Committee

PPRI AB as
Technical Steering
Committee

Members:

- **Mr Zaheer-Ud-Din Babar**, Professor in Medicines and Healthcare, University of Huddersfield, UK
- **Ms. Dimitra Panteli**, Programme Manager / Senior Health Systems Analyst - European Observatory on Health Systems and Policies, Brussels, Belgium
- **Ms Aukje Mantel-Teeuwisse**, Utrecht University, Professor in Pharmacy and Global Health, Managing Director of WHO Collaborating Centre of Pharmaceutical Policy and Regulation, Utrecht, The Netherlands
- **Ms Veronika Wirtz**, Professor in the Department of Global Health at the Boston University School of Public Health, Director of the WHO Collaborating Center in Pharmaceutical Policy, Boston, USA
- **Ms. Fatima Suleman**, Professor in the School of Health Sciences, University of KwaZulu-Natal and Director of the WHO Collaborating Centre for Pharmaceutical Policy and Evidence Based Practice, Durban, South Africa
- **Mr. Jaime Espin Balbino**, Professor, Andalusian School of Public Health, Granada, Spain

PPRI Conference 2024 – Draft programme Day 1

Morning session

Welcome

- Federal Minister of Social Affairs, Health, Care and Consumer Protection **Johannes Rauch**
- Executive Director **Herwig Ostermann**, Gesundheit Österreich GmbH (GÖG / Austrian National Public Health Institute)
- WHO Representative **Klara Tisocki**, Team Lead for Medicines and Health Products Pricing and Affordability in the Department of Health Products Policy, World Health Organization Headquarters
 - European Commission representative **Harald Mische**, DG SANTE (video message)
- Head of WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies **Sabine Vogler** (GÖG / Austrian National Public Health Institute)

Keynote presentation: Meindert Boysen (NICE, UK)

Stakeholder roundtable:

- **Johan Ponten**, TLV, Sweden
- **Thomas Allvin**, EFPIA
- **Maja Graf**, International Generic and Biosimilar Medicines Association (IGBA)
 - **Anca Toma**, European Patients Forum
 - **Giulia Segafredo**, Medicines Patent Pool

Lunch break

Afternoon session

Break-out session I (3 strands)

- 1 keynote and 2 abstract presentations per strand

- **Tamás Evetovits**, Head of WHO Barcelona Office for Health Systems Financing, Division of Country Health Policies and Systems
 - Members of the Scientific Programme Committee

2 oral abstract
presentations per strand

In total: 6

Poster walk during the coffee break

Moderated poster session (3 strands)

4 brief poster
presentations per strand

In total: 12

Evening Reception

Social Dinner (only for invited guests)

PPRI Conference 2024 – Draft programme Day 2

Early bird session (Meet the editors)

- Journal of Pharmaceutical Policy and Practice (JOPPP), Zaheer-Ud-Din Babar
- International Journal of Technology Assessment in Health Care, Claudia Wild
 - Health Policy (tbc)
- Adis HEOR Journals (Applied Health Economics and Health Policy, Pharmacoeconomics, Pharmacoeconomics - Open), Tim Wrightson (video message)

Key Note presentation:
Sarah Garner, WHO Regional Office for Europe

Country Poster Presentations

Country Poster walk during the coffee break

Break-out session II
- Keynote and 3 abstract presentations per Strand

- Key notes by members of the Scientific Programme Committee and/or PPRI Advisory Board

3 oral abstract
presentations per strand

In total: 9

Lunch break

Afternoon session

Workshops:

- How the Euripid collaboration contributes to improving access to pharmaceuticals
 - Cross regional HTA partnerships (tbc)
 - Topic 3 (tbc)

Keynote presentation:
Anja Schiel, Norwegian Medicines Agency

Conclusions, awards and closure

PPRI Conference 2024 – Call for abstracts

Different types of submissions and presentations

1. Oral presentation (max. 10min + Q&A)
2. Brief poster presentations (max. 5min + Q&A)
3. Posters (without oral presentation)

Size and language: max. 400 words; in English

Launched on 28 Nov. 2023; closed on 15 January 2024 (extended deadline)

Webinar for PPRI network members “Drafting abstracts for a conference”, 18 December 2023

Received abstracts: 69 submissions

Publication in Conference Supplement to the Journal of Pharmaceutical Policy and Practice (JOPPP)

Evaluation by the Scientific Programme Committee following defined criteria

Evaluation meeting took place on 02 February 2024

Any ideas for further promotion?



PPRI Network Meeting, Vienna

24 April 2024



Gesundheit Österreich
GmbH 

PPRI Network Meeting

Vienna, Austrian Social Insurance

Time	Preliminary agenda
12.00 – 13.00	<i>Networking lunch</i>
13.00 – 13.20	Welcome and introduction
13.20 – 13.40	PPRI dissemination policy
13.40 – 14.45	Use of consumption and expenditure data <ul style="list-style-type: none"> –Overview –Italy (tbc) –Germany (tbc)
14.45 – 15.15	<i>Coffee & tea</i>
15.15 – 16.00	Update PPRI Indicators (interactive session)
16.00 – 17.00	Austrian pharmaceutical system <ul style="list-style-type: none"> –MoH (tbc) –Social Insurance (tbc) –Vienna Hospital Fund (tba)
17.00 – 17.15	Next steps & outlook

PPRI Pharma Briefs & Report

PPRI Pharma Brief Austria 2023
published



PPRI Pharma Brief Germany 2024
(draft for review)

PPRI Pharma Report 2024
Planned to be launched in 2024

→ Indicators

PPRI Indicators – finally!

[LINK](#)

Link not working externally –
updated link will be shared
after data validation with PPRI
countries

Plan to be sent to the PPRI
member countries for review

- Validation (internal)
- Publication (separate URL)

PPRI Indicators / Backup slides

PPRI Indicators - 2023

2.1 Scope of price control for medicines (for validation)



Indicator: 2.1 Scope of price control for medicines (for validation) 2023


Countries: All countries

Export

This indicator add-ons in:

- PPRI countries (n=52)
- Countries of the WHO European Region (included in PPRI; n=43)
- EU-28 and EFTA countries (excl. LI; n=31)
- EU-27 and EFTA countries (excl. LI; n=30)
- EU-28*
- EU-27**
- Select Countries

* 1 July 2013 - 31 January 2020
** since 1 February 2020



PPRI Indicators - 2023

3.2 Methodology to determine the reference price under external price referencing (for validation)




Indicator: 3.2 Methodology to determine the reference price under external price referencing (for validation) 2023

Countries: All countries

Export

The indicator describes the methodology the PPRI countries apply to determine the benchmark price under external price referencing (EPR). In the EPR policy, the price(s) of a medicine of one or several countries are used to derive a benchmark (or a reference price) for the purpose of setting or negotiating the price of the product in the own country. This policy may be used as an initial benchmark and may be followed by the use of further policies of the given medicine in the pricing or reimbursement process.



PPRI Indicators / Backup slides

- 2.1 Scope of price control for medicines (for validation)
- 2.2 Price types regulated (for validation)
- 3.1 Use of External Price Referencing (for validation)
- 3.2 Methodology to determine the reference price under external price referencing (for validation)
- 3.4 Number of reference countries to determine the reference price under external price referencing (for validation)
- 3.6 Scope of EPR: sectors covered (for validation)
- 4.1 Generic price link (for validation)
 - 4.1.1 Generic price link: Extent of price difference for generics (for validation)
 - 4.1.2 Generic price link: Medicines targeted (for validation)
- 4.2 Biosimilar price link (for validation)
 - 4.2.1 Biosimilar price link: Extent of price difference for biosimilars (for validation)
 - 4.2.2 Biosimilar price link: Medicines targeted (for validation)
- 4.3 Generic and biosimilar price link (for validation)
- 5.1 Value-based pricing for new medicines (for validation)
- 6.1 Tendering in place (for validation)
 - 6.1.1 Use of tendering in outpatient sector
 - 6.1.2 Use of tendering in inpatient sector
- 8.1 Regulation of wholesale remuneration (for validation)
 - 8.1.1 Medicines covered by wholesale remuneration regulation (for validation)
- 8.2 Regulation of pharmacy remuneration (for validation)
 - 8.2.1 Medicines covered by pharmacy remuneration regulation (for validation)
- 9.1 VAT on medicines (for validation)
 - 9.1.1 Scope of medicines covered by VAT (for validation)
 - 9.1.2 Value-added tax rates for medicines
 - 9.1.3 Valued-added tax on medicines compared to value-added tax

- 11.1 Reimbursement lists
 - 11.1.1 Reimbursement list(s) in the outpatient sector (for validation)
 - 11.1.2 Reimbursement lists (hospital pharmaceutical formularies, HPF) in the inpatient sector (for validation)
- 12.1 Reimbursement rates of medicines included in reimbursement lists in the outpatient sector (for validation)
- 12.2 Reimbursement rates of medicines used in hospitals (for validation)
- 13.1 Co-payments for funded medicines
 - 13.1.1 Co-payments for funded medicines in the outpatient sector (for validation)
 - 13.1.2 Co-payments for funded medicines in the inpatient sector (for validation)
- 13.2.1 Types of co-payments in place in the outpatient sector (for validation)
- 14.1 Reference price system (for validation)
- 14.2 Reference price system - Cluster of reference groups (for validation)
- 14.4 Reference price system - Definition of the reference price (for validation)
- 15.1 Prescribing by International Non-Proprietary Name (INN) - use (for validation)
- 15.2 Prescribing by International Non-Proprietary Name (INN) - level of requirement (for validation)
- 16.1 Generic substitution - use (for validation)
- 16.2 Generic substitution - level of requirement (for validation)
- 16.3 Biosimilar substitution - use (for validation)
- 16.4 Biosimilar substitution - level of requirements (for validation)
- 16.5 Generic and biosimilar substitution (for validation)
- 18.1 Implementation of horizon scanning (for validation)
- 18.2 Use of horizon scanning (for validation)
- 19.1 Implementation of health technology assessment (HTA) (for validation)
- 19.2 Use of health technology assessment (HTA) (for validation)
- 22.1 Managed Entry Agreements (MEA) (for validation)
- 22.2 Managed Entry Agreements for medicines for use in the inpatient and outpatient sectors (for validation)
- 22.3 Types of managed entry agreements (MEA) (for validation)
- 22.4 Number of managed entry agreements (MEA) for medicines (for validation)

PPRI@20: 2005 - 2025



PPRI Advisory Board Term

Institution	AB Position
PPRI funder (MoH)	Permanent member
European and international institutions	Permanent members
PPRI member countries	Rotating members (at least 2 years)

1st PPRI AB: 2017 – 2020

2nd PPRI AB: 2021 - 2023

“should reflect diversity in terms of income and size of the country they represent, geographical distribution and organisation of their health care and pharmaceutical system”

medical devices perspective

PPRI Advisory Board Term


Suggestion to prolong the
PPRI Advisory Board Term till end of 2025

To be
discussed

Implementation:
Change of the term in the
Tasks & Procedures document



Thank you for your support!



PPRI Secretariat

**Gesundheit Österreich GmbH (GÖG /
Austrian National Public Health Institute)**

Stubenring 6

1010 Vienna

M: +43 676 848 191 – 104 (Sabine Vogler)

T: +43 51561-102- (Nina Zimmermann, PPRI Conference)

ppri@goeg.at & ppriconference@goeg.at

ppri.goeg.at & www.goeg.at